NYSE:GKOS Glaukos (GKOS) Stock Price, News & Analysis → Was the Great Financial Crisis fun? (From Brooks Enterprises) (Ad) Free GKOS Stock Alerts $113.91 -0.05 (-0.04%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$113.22▼$115.5550-Day Range$89.47▼$114.7252-Week Range$59.22▼$115.78Volume308,537 shsAverage Volume375,506 shsMarket Capitalization$5.74 billionP/E RatioN/ADividend YieldN/APrice Target$112.27 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Glaukos alerts: Email Address Glaukos MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.82 Rating ScoreUpside/Downside1.4% Downside$112.27 Price TargetShort InterestHealthy6.45% of Shares Sold ShortDividend StrengthN/ASustainability-0.90Upright™ Environmental ScoreNews Sentiment0.84Based on 20 Articles This WeekInsider TradingSelling Shares$8.39 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.26) to ($1.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.56 out of 5 starsMedical Sector231st out of 904 stocksSurgical & Medical Instruments Industry29th out of 97 stocks 2.4 Analyst's Opinion Consensus RatingGlaukos has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageGlaukos has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Glaukos' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.45% of the outstanding shares of Glaukos have been sold short.Short Interest Ratio / Days to CoverGlaukos has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Glaukos has recently decreased by 7.41%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGlaukos does not currently pay a dividend.Dividend GrowthGlaukos does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlaukos has received a 65.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical laser systems", "Medical technology engineering", and "Surgical instruments" products. See details.Environmental SustainabilityThe Environmental Impact score for Glaukos is -0.90. Previous Next 2.7 News and Social Media Coverage News SentimentGlaukos has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Glaukos this week, compared to 5 articles on an average week.MarketBeat FollowsOnly 3 people have added Glaukos to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Glaukos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,387,713.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Glaukos is held by insiders.Percentage Held by Institutions99.04% of the stock of Glaukos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Glaukos' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Glaukos are expected to grow in the coming year, from ($2.26) to ($1.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Glaukos is -39.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Glaukos is -39.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlaukos has a P/B Ratio of 12.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Glaukos' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar. For one main reason.In answer to this issue, we have released a Special Report to the public. About Glaukos Stock (NYSE:GKOS)Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.Read More GKOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GKOS Stock News HeadlinesJune 6 at 7:33 AM | insidertrades.comGlaukos Co. (NYSE:GKOS) COO Sells $283,750.00 in StockJune 4, 2024 | insidertrades.comGlaukos Co. (NYSE:GKOS) Director Sells $560,000.00 in StockMay 17, 2024 | insidertrades.comGlaukos Co. (NYSE:GKOS) Director Marc Stapley Sells 6,250 SharesMay 15, 2024 | insidertrades.comGlaukos Co. (NYSE:GKOS) CFO Alex R. Thurman Sells 353 SharesMay 9, 2024 | insidertrades.comGlaukos Co. (NYSE:GKOS) COO Joseph E. Gilliam Sells 105 SharesJune 7 at 1:18 AM | americanbankingnews.comGlaukos (NYSE:GKOS) Sets New 52-Week High on Analyst UpgradeJune 6 at 7:34 AM | americanbankingnews.comGlaukos Co. (NYSE:GKOS) COO Joseph E. Gilliam Sells 2,500 SharesJune 6 at 4:12 AM | americanbankingnews.comGlaukos (NYSE:GKOS) Price Target Raised to $130.00June 5 at 2:34 AM | americanbankingnews.comWells Fargo & Company Increases Glaukos (NYSE:GKOS) Price Target to $120.00June 4, 2024 | americanbankingnews.comGlaukos Co. (NYSE:GKOS) Sees Large Decline in Short InterestMay 30, 2024 | seekingalpha.comGlaukos Stock: Still Unproven Whether A New Bull Market Has BegunMay 28, 2024 | businesswire.comGlaukos Announces Participation in Upcoming Investor ConferencesMay 22, 2024 | markets.businessinsider.comDeep Dive Into Glaukos Stock: Analyst Perspectives (12 Ratings)May 8, 2024 | finance.yahoo.comEarnings Update: Here's Why Analysts Just Lifted Their Glaukos Corporation (NYSE:GKOS) Price Target To US$113May 6, 2024 | msn.comJefferies Upgrades Glaukos (GKOS)May 6, 2024 | msn.comGlaukos rises on upgrade to Buy at JefferiesMay 6, 2024 | markets.businessinsider.comBuy Rating on Glaukos with Strong Growth Prospects for iDose and MIGS Market ShareMay 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Glaukos on Strong Q1 Performance and Promising iDose ProspectsMay 2, 2024 | msn.comGlaukos Corporation (NYSE:GKOS) Q1 2024 Earnings Call TranscriptMay 2, 2024 | finance.yahoo.comGlaukos Corp (GKOS) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and Strategic ...May 2, 2024 | gurufocus.comQ1 2024 Glaukos Corp Earnings Call TranscriptMay 2, 2024 | investing.comGlaukos Corp (GKOS) Earnings Dates & ReportsMay 2, 2024 | msn.comGKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q1 2024May 1, 2024 | finance.yahoo.comGlaukos Announces First Quarter 2024 Financial ResultsMay 1, 2024 | finance.yahoo.comGlaukos Corp (GKOS) Q1 2024 Earnings: Misses Analyst EPS Forecast, Surpasses Revenue ExpectationsSee More Headlines Receive GKOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today6/08/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:GKOS CUSIPN/A CIK1192448 Webwww.glaukos.com Phone(949) 367-9600Fax949-367-9984Employees907Year FoundedN/APrice Target and Rating Average Stock Price Target$112.27 High Stock Price Target$130.00 Low Stock Price Target$65.00 Potential Upside/Downside-1.4%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($2.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-134,660,000.00 Net Margins-43.15% Pretax Margin-42.88% Return on Equity-24.69% Return on Assets-12.27% Debt Debt-to-Equity Ratio0.78 Current Ratio5.38 Quick Ratio4.68 Sales & Book Value Annual Sales$314.71 million Price / Sales18.23 Cash FlowN/A Price / Cash FlowN/A Book Value$9.46 per share Price / Book12.04Miscellaneous Outstanding Shares50,370,000Free Float47,144,000Market Cap$5.74 billion OptionableOptionable Beta1.09 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Thomas William Burns (Age 63)Chairman & CEO Comp: $774.9kMr. Joseph E. Gilliam (Age 48)President & COO Comp: $1.18MMr. Alex R. Thurman (Age 54)Senior VP & CFO Comp: $621.24kDr. Tomas Navratil Ph.D. (Age 47)Chief Development Officer Comp: $866.18kDr. Mory Gharib Ph.D.Co-FounderMr. Christopher William LewisVice President of Investor Relations & Corporate AffairsMs. Diana A. SchererVP of Compliance & Deputy General CounselMs. Michele M. AllegrettoSenior Vice President of Human ResourcesMr. Chris M. Calcaterra (Age 64)Executive Vice President of Global Commercial Operations Comp: $198.66kMs. Jane E. Rady (Age 76)Senior Vice President of Corporate Strategy & Business Development More ExecutivesKey CompetitorsWest Pharmaceutical ServicesNYSE:WSTBaxter InternationalNYSE:BAXInsuletNASDAQ:PODDShockwave MedicalNASDAQ:SWAVTeleflexNYSE:TFXView All CompetitorsInsiders & InstitutionsJoseph E GilliamSold 2,500 sharesTotal: $283,750.00 ($113.50/share)Gilbert H KlimanSold 5,000 sharesTotal: $560,000.00 ($112.00/share)Opaleye Management Inc.Bought 8,576 shares on 5/29/2024Ownership: 0.017%Cetera Advisors LLCBought 2,257 shares on 5/24/2024Ownership: 0.004%Castleark Management LLCSold 2,650 shares on 5/17/2024Ownership: 0.129%View All Insider TransactionsView All Institutional Transactions GKOS Stock Analysis - Frequently Asked Questions Should I buy or sell Glaukos stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GKOS shares. View GKOS analyst ratings or view top-rated stocks. What is Glaukos' stock price target for 2024? 11 analysts have issued 1 year price objectives for Glaukos' stock. Their GKOS share price targets range from $65.00 to $130.00. On average, they expect the company's share price to reach $112.27 in the next year. This suggests that the stock has a possible downside of 1.4%. View analysts price targets for GKOS or view top-rated stocks among Wall Street analysts. How have GKOS shares performed in 2024? Glaukos' stock was trading at $79.49 at the start of the year. Since then, GKOS shares have increased by 43.3% and is now trading at $113.91. View the best growth stocks for 2024 here. Are investors shorting Glaukos? Glaukos saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 3,250,000 shares, a decline of 7.4% from the April 30th total of 3,510,000 shares. Based on an average daily volume of 495,000 shares, the short-interest ratio is presently 6.6 days. View Glaukos' Short Interest. When is Glaukos' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our GKOS earnings forecast. How were Glaukos' earnings last quarter? Glaukos Co. (NYSE:GKOS) posted its earnings results on Wednesday, May, 1st. The medical instruments supplier reported ($0.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by $0.12. The medical instruments supplier had revenue of $85.60 million for the quarter, compared to analyst estimates of $79.60 million. Glaukos had a negative net margin of 43.15% and a negative trailing twelve-month return on equity of 24.69%. Glaukos's revenue for the quarter was up 15.8% compared to the same quarter last year. During the same quarter last year, the company earned ($0.59) earnings per share. What ETFs hold Glaukos' stock? ETFs with the largest weight of Glaukos (NYSE:GKOS) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), Alger Weatherbie Enduring Growth ETF (AWEG), SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P SmallCap Momentum ETF (XSMO), Fidelity Disruptive Medicine ETF (FMED), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Principal Healthcare Innovators ETF (BTEC) and SPDR S&P 600 Small Cap Growth ETF (SLYG). What guidance has Glaukos issued on next quarter's earnings? Glaukos updated its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $357.0 million-$365.0 million, compared to the consensus revenue estimate of $356.7 million. What is Thomas W. Burns' approval rating as Glaukos' CEO? 10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Glaukos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA). When did Glaukos IPO? Glaukos (GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers. Who are Glaukos' major shareholders? Glaukos' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.54%), Brown Capital Management LLC (4.23%), Janus Henderson Group PLC (3.20%), Riverbridge Partners LLC (1.06%), Iron Triangle Partners LP (0.85%) and Allspring Global Investments Holdings LLC (0.34%). Insiders that own company stock include Alex R Thurman, Gilbert H Kliman, Joseph E Gilliam, Marc Stapley, Mark J Foley and Thomas William Burns. View institutional ownership trends. How do I buy shares of Glaukos? Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:GKOS) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Glaukos Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Glaukos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.